$SCYX: Scynexis presents interim sub-analysis of P
Post# of 23232
Posted On: 06/20/2016 12:49:25 PM
$SCYX: Scynexis presents interim sub-analysis of Phase 1 studies, which demonstrated that the oral bioavailability of SCY-078 at ASM Microbe 2016
SCY-078 shown to be the first glucan synthase inhibitor with high oral bioavailability in humans Fungicidal activity of SCY-078 demonstrated against multiple Candida species, including difficult-to-treat strains SCY-078 progressing to next stages of clinical development in invasive candidiasis with both intravenous and oral formulations.
Co presented an interim sub-analysis of Phase 1 studies, which demonstrated that the oral bioavailability of SCY-078, its novel antifungal glucan synthesis inhibitor, allows to readily achieve the target blood exposure required to fight an Invasive Candida infection. Additionally, in a preclinical study, SCY-078 showed rapid in vitro fungicidal activity against multiple Candida species. Both data sets were presented in podium presentations at ASM Microbe 2016 in Boston from June 16 through 20, 2016.
"The confirmation of significant oral bioavailability and fungicidal activity against Candida, coupled with the positive clinical results from our recently released Phase 2 proof-of-concept study of orally administered SCY-078 in a mucocutaneous Candida infection (vulvovaginal candidiasis), further supports our current plans to advance the development of SCY-078 in invasive candidiasis."
SCY-078 shown to be the first glucan synthase inhibitor with high oral bioavailability in humans Fungicidal activity of SCY-078 demonstrated against multiple Candida species, including difficult-to-treat strains SCY-078 progressing to next stages of clinical development in invasive candidiasis with both intravenous and oral formulations.
Co presented an interim sub-analysis of Phase 1 studies, which demonstrated that the oral bioavailability of SCY-078, its novel antifungal glucan synthesis inhibitor, allows to readily achieve the target blood exposure required to fight an Invasive Candida infection. Additionally, in a preclinical study, SCY-078 showed rapid in vitro fungicidal activity against multiple Candida species. Both data sets were presented in podium presentations at ASM Microbe 2016 in Boston from June 16 through 20, 2016.
"The confirmation of significant oral bioavailability and fungicidal activity against Candida, coupled with the positive clinical results from our recently released Phase 2 proof-of-concept study of orally administered SCY-078 in a mucocutaneous Candida infection (vulvovaginal candidiasis), further supports our current plans to advance the development of SCY-078 in invasive candidiasis."
(1)
(0)